Your browser is no longer supported. Please, upgrade your browser.
Settings
PULM Pulmatrix, Inc. daily Stock Chart
PULM [NASD]
Pulmatrix, Inc.
Index- P/E- EPS (ttm)-1.01 Insider Own- Shs Outstand24.38M Perf Week-4.69%
Market Cap31.76M Forward P/E- EPS next Y-1.44 Insider Trans- Shs Float- Perf Month-8.96%
Income-20.10M PEG- EPS next Q-0.40 Inst Own21.60% Short Float- Perf Quarter-25.15%
Sales10.70M P/S2.97 EPS this Y75.30% Inst Trans90.89% Short Ratio0.36 Perf Half Y-15.28%
Book/sh0.57 P/B2.14 EPS next Y-6.70% ROA-39.90% Target Price- Perf Year40.23%
Cash/sh1.05 P/C1.16 EPS next 5Y- ROE-115.60% 52W Range0.61 - 2.06 Perf YTD41.86%
Dividend- P/FCF- EPS past 5Y48.70% ROI- 52W High-45.26% Beta1.68
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low84.34% ATR0.10
Employees22 Current Ratio2.00 Sales Q/Q-27.10% Oper. Margin- RSI (14)29.12 Volatility5.98% 6.90%
OptionableNo Debt/Eq0.00 EPS Q/Q88.20% Profit Margin- Rel Volume1.86 Prev Close1.22
ShortableYes LT Debt/Eq0.00 EarningsAug 17 BMO Payout- Avg Volume953.76K Price1.13
Recom- SMA20-14.09% SMA50-27.04% SMA200-16.56% Volume1,003,795 Change-7.79%
Feb-09-18Initiated H.C. Wainwright Buy $5
Aug-07-20 09:00AM  
Jul-08-20 08:30AM  
Jun-26-20 09:00AM  
May-27-20 09:00AM  
May-14-20 09:00AM  
Apr-29-20 10:02AM  
Apr-16-20 05:25PM  
08:30AM  
Mar-26-20 09:00AM  
Jan-31-20 07:20AM  
Jan-30-20 08:00AM  
Jan-16-20 12:05PM  
Jan-06-20 08:58AM  
Jan-03-20 09:55AM  
Jan-02-20 08:51AM  
Nov-04-19 09:15AM  
Nov-01-19 09:00AM  
Sep-18-19 09:30AM  
Aug-19-19 09:25AM  
Aug-05-19 09:00AM  
Jun-07-19 10:25AM  
Jun-06-19 06:42AM  
May-16-19 09:10AM  
May-15-19 09:00AM  
Apr-15-19 09:00AM  
Apr-08-19 04:29PM  
Apr-03-19 09:30PM  
Apr-01-19 05:33PM  
02:34PM  
09:00AM  
Mar-14-19 09:45AM  
Mar-12-19 12:22PM  
Mar-08-19 01:00PM  
Feb-19-19 09:00AM  
Feb-12-19 09:30AM  
Feb-08-19 07:00AM  
Feb-07-19 09:00AM  
Feb-06-19 12:15PM  
09:00AM  
Feb-05-19 12:45PM  
11:14AM  
Jan-31-19 01:24PM  
Jan-30-19 09:52PM  
04:01PM  
Jan-28-19 11:27PM  
04:18PM  
Nov-29-18 05:00AM  
Nov-21-18 09:30AM  
Nov-15-18 09:30AM  
Nov-14-18 04:30PM  
Sep-18-18 11:45AM  
Sep-17-18 09:35AM  
Aug-28-18 10:00AM  
Aug-03-18 09:00AM  
Jul-23-18 10:13AM  
Jul-20-18 07:20AM  
Jul-17-18 09:00AM  
Jun-25-18 08:30AM  
Jun-13-18 09:35AM  
Jun-07-18 09:30AM  
Jun-04-18 07:40AM  
07:20AM  
May-25-18 12:49PM  
May-17-18 09:35AM  
May-11-18 09:00AM  
Mar-29-18 12:02AM  
Mar-13-18 04:42PM  
Mar-09-18 09:46AM  
Feb-12-18 09:35AM  
Jan-29-18 08:00AM  
Jan-28-18 11:01PM  
Jan-25-18 10:30AM  
Jan-24-18 12:00PM  
Jan-22-18 10:25AM  
Dec-19-17 11:45AM  
Dec-04-17 05:10PM  
Nov-29-17 08:47AM  
Nov-14-17 01:00PM  
Nov-09-17 04:30PM  
Oct-31-17 11:00AM  
Oct-30-17 09:45AM  
Oct-24-17 10:00AM  
Oct-11-17 02:14PM  
Oct-03-17 09:45AM  
Sep-27-17 08:10AM  
Sep-21-17 09:50AM  
Sep-20-17 09:40AM  
Sep-19-17 05:57PM  
02:04PM  
11:00AM  
Sep-08-17 09:30AM  
Sep-06-17 08:32AM  
08:00AM  
04:37AM  
Sep-05-17 10:00AM  
Aug-04-17 08:55AM  
Aug-03-17 10:30AM  
Jul-31-17 10:00AM  
Jun-26-17 10:00AM  
Jun-15-17 12:13PM  
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a research collaboration with Nocion Therapeutics Inc. to explore technologies that enable and improve inhaled drug delivery. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.